This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
What Lies Ahead for China ETFs in the Year of Rabbit?
by Sanghamitra Saha
The Chinese markets have recently made a comeback. Can the rally last in the year of water rabbit?
Top-Performing ETF Areas of Last Week
by Sanghamitra Saha
Wall Street recorded a moderate performance last week. But the final week of the year was not that bad. This was probably because of the muted Santa Clause rally.
4 Best Areas of Q4 Up At Least 20% & Their Top ETFs
by Sanghamitra Saha
The fourth quarter of 2022 is just about to wrap up. The broader market has posted mixed performance during this time frame.
5 Best-Performing ETFs of Last Week
by Sanghamitra Saha
Wall Street was downbeat last week on rising rate fears and recessionary concerns.
China ETFs Rallying: Top Gainers Past Month
by Sanghamitra Saha
China ETFs have been rallying of late to reflect easing Covid controls and a sweeping rescue package to bail out developers.
Best Biotech Stocks & ETFs for mRNA, Gene Editing
by Neena Mishra
Here is what you should know about investing in these life changing technologies.
Best-Performing ETF Areas of Last Week
by Sanghamitra Saha
Last week was slightly downbeat for Wall Street on talks of a capital gain tax hike with three big U.S. indexes remaining in the red.
4 China ETFs Beating S&P 500 in its Worst Week Since 2008
by Sanghamitra Saha
Check these China ETFs that beat the S&P 500 in the past week, which was U.S. equities??? worst-ever since 2008.
Cancer-Fighting Stocks & ETF: What You Need to Know
by Neena Mishra
Many biotech stocks soared after they presented very promising cancer treatment results at the ASCO conference
Why Cancer-Fighting Stocks & ETFs Are Soaring
by Neena Mishra
The cancer immunotherapy ETF is soaring today as some of its holdings presented very promising results at the ASCO conference. Find out more on the podcast.